Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice

Bibliographic Details
Main Author: Ferreira, Aníbal
Publication Date: 2019
Other Authors: Pinto, Bruno, Navarro, David, Aniceto, João, Neves, Pedro L., Ponce, Pedro
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://doi.org/10.1590/2175-8239-JBN-2018-0142
Summary: INTRODUCTION: Hyperphosphatemia is a serious consequence of chronic kidney disease and has been associated with an increased risk for cardiovascular disease. Controlling serum phosphorus levels in patients on dialysis is a challenge for the clinicians and implies, in most cases, the use of phosphate binders (PB). Part of the reason for this challenge is poor adherence to treatment because of the high pill burden in this patient group. OBJECTIVE: To assess the real-world effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus levels and determine the associated pill burden. METHODS: A multicenter, quantitative, retrospective, before-after study was conducted with patients receiving online hemodiafiltration. Patients who switched to SO as a part of routine care were included in the study. PB treatment, number of pills, serum phosphorus levels, and intravenous iron medication and dosage were collected monthly during the six months of treatment with either PB or SO. RESULTS: A total of 42 patients were included in the study. After switching from a PB to SO, the prescribed pills/day was reduced 67% from 6 pills/day to 2 pills/day (p < 0.001) and the frequency of pill intake was lowered from 3 times/day to 2 times/day (p < 0.001). During the treatment with SO, the proportion of patients with serum phosphorus ≤ 5.5 mg/dL increased from 33.3% at baseline to 45% after six months of treatment. CONCLUSION: During the six-month follow-up with SO, serum phosphorus levels were controlled with one third of the pills/day compared to other PB.
id RCAP_47e635e4df5cbe4c473b76e22df536e2
oai_identifier_str oai:run.unl.pt:10362/82245
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practiceA retrospective studyMedicine(all)SDG 3 - Good Health and Well-beingINTRODUCTION: Hyperphosphatemia is a serious consequence of chronic kidney disease and has been associated with an increased risk for cardiovascular disease. Controlling serum phosphorus levels in patients on dialysis is a challenge for the clinicians and implies, in most cases, the use of phosphate binders (PB). Part of the reason for this challenge is poor adherence to treatment because of the high pill burden in this patient group. OBJECTIVE: To assess the real-world effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus levels and determine the associated pill burden. METHODS: A multicenter, quantitative, retrospective, before-after study was conducted with patients receiving online hemodiafiltration. Patients who switched to SO as a part of routine care were included in the study. PB treatment, number of pills, serum phosphorus levels, and intravenous iron medication and dosage were collected monthly during the six months of treatment with either PB or SO. RESULTS: A total of 42 patients were included in the study. After switching from a PB to SO, the prescribed pills/day was reduced 67% from 6 pills/day to 2 pills/day (p < 0.001) and the frequency of pill intake was lowered from 3 times/day to 2 times/day (p < 0.001). During the treatment with SO, the proportion of patients with serum phosphorus ≤ 5.5 mg/dL increased from 33.3% at baseline to 45% after six months of treatment. CONCLUSION: During the six-month follow-up with SO, serum phosphorus levels were controlled with one third of the pills/day compared to other PB.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNFerreira, AníbalPinto, BrunoNavarro, DavidAniceto, JoãoNeves, Pedro L.Ponce, Pedro2019-09-24T22:59:44Z2019-04-012019-04-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article7application/pdfhttps://doi.org/10.1590/2175-8239-JBN-2018-0142eng0101-2800PURE: 14787583http://www.scopus.com/inward/record.url?scp=85072057346&partnerID=8YFLogxKhttps://doi.org/10.1590/2175-8239-JBN-2018-0142info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-22T17:41:13Zoai:run.unl.pt:10362/82245Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T17:12:27.910255Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice
A retrospective study
title Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice
spellingShingle Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice
Ferreira, Aníbal
Medicine(all)
SDG 3 - Good Health and Well-being
title_short Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice
title_full Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice
title_fullStr Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice
title_full_unstemmed Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice
title_sort Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice
author Ferreira, Aníbal
author_facet Ferreira, Aníbal
Pinto, Bruno
Navarro, David
Aniceto, João
Neves, Pedro L.
Ponce, Pedro
author_role author
author2 Pinto, Bruno
Navarro, David
Aniceto, João
Neves, Pedro L.
Ponce, Pedro
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Ferreira, Aníbal
Pinto, Bruno
Navarro, David
Aniceto, João
Neves, Pedro L.
Ponce, Pedro
dc.subject.por.fl_str_mv Medicine(all)
SDG 3 - Good Health and Well-being
topic Medicine(all)
SDG 3 - Good Health and Well-being
description INTRODUCTION: Hyperphosphatemia is a serious consequence of chronic kidney disease and has been associated with an increased risk for cardiovascular disease. Controlling serum phosphorus levels in patients on dialysis is a challenge for the clinicians and implies, in most cases, the use of phosphate binders (PB). Part of the reason for this challenge is poor adherence to treatment because of the high pill burden in this patient group. OBJECTIVE: To assess the real-world effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus levels and determine the associated pill burden. METHODS: A multicenter, quantitative, retrospective, before-after study was conducted with patients receiving online hemodiafiltration. Patients who switched to SO as a part of routine care were included in the study. PB treatment, number of pills, serum phosphorus levels, and intravenous iron medication and dosage were collected monthly during the six months of treatment with either PB or SO. RESULTS: A total of 42 patients were included in the study. After switching from a PB to SO, the prescribed pills/day was reduced 67% from 6 pills/day to 2 pills/day (p < 0.001) and the frequency of pill intake was lowered from 3 times/day to 2 times/day (p < 0.001). During the treatment with SO, the proportion of patients with serum phosphorus ≤ 5.5 mg/dL increased from 33.3% at baseline to 45% after six months of treatment. CONCLUSION: During the six-month follow-up with SO, serum phosphorus levels were controlled with one third of the pills/day compared to other PB.
publishDate 2019
dc.date.none.fl_str_mv 2019-09-24T22:59:44Z
2019-04-01
2019-04-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.1590/2175-8239-JBN-2018-0142
url https://doi.org/10.1590/2175-8239-JBN-2018-0142
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0101-2800
PURE: 14787583
http://www.scopus.com/inward/record.url?scp=85072057346&partnerID=8YFLogxK
https://doi.org/10.1590/2175-8239-JBN-2018-0142
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 7
application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833596518897025024